Just emailed ARRY asking them the same question.
Silent period prior to buyout ?
The presentations are on the AACR website.
Something tells me, the company is in buyout talks. When the buyout price is in the 8.00-9.00 range the shareholders will be jumping for joy as they are mostly in the red as we speak. Investment Psychology at its best.
Short interest went down by 2 million shares, now sitting at 21.3 million shares short.
Also the lowest short interest in the last 12 months, tomorrow might be a good time to start covering :)
An SEC form similar to the Schedule 13D used to report a party's ownership of stock that is over 5% of the company. Schedule 13G is shorter and requires less information from the filing party. Ownership of over 5% in a publicly-traded stock is considered to be significant ownership, and therefore must be reported to the public.
BlackRock Inc was a buyer, contrary to some of the previous post. They hold 6.5%of the float as Redmile holds close to 16% of the float
I did my part (again) while the pipeline is strong , the leadership has definitely let down the shareholders.
I did mention the continuous cheerleading by the CEO with his favorite 2 phrases "UPCOMING CATALYST" and his new phrase "NEXY VALUE DRIVER" with added no value what so ever. Go to the archives and listen for yourself.
We have given him ample of time to produce "shareholder value" it might be time for the institutions to put some pressure on Mr Squarer and have him replaced. JMHO
• Loxo's collaboration with Array BioPharma continues to generate compelling and differentiated chemical matter. Loxo has used its multi-target, prioritize-by-success collaboration structure to focus on RET and FGFR.
Clinical Validation for LOXO-101 Published in Cancer Discovery